Patent · US Active

Gene therapy for the treatment of a retinal degeneration disease

US11400167B2 · kind B2 · utility

0Cited by

3References

20Claims

0Family size

Assignee

EYESERV GMBH · DE

Inventors

Stylianos Michalakis · Munich, DE
Martin Biel · Starnberg, DE
Mathias Seeliger · Rottenburg am Neckar, DE
Christian Schoen · Dortmund, DE

Key dates

Filing date	Aug 22, 2018
Grant date	Aug 2, 2022
Priority date	—
Expiry date	Oct 30, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/48
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a polynucleotide configured for the treatment of a retinal degeneration disease, such as retinitis pigmentosa (RP), a nucleic acid vector comprising said polynucleotide, a pharmaceutical composition comprising said nucleic acid vector, a kit comprising said polynucleotide or said nucleic acid vector, a method of making said nucleic acid vector, and a method for treating a retinal degeneration disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.